Dr Callander on Investigational Maintenance Regimens in Multiple Myeloma
Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.
Source: onclive.com
Stay updated with breaking news from Forte Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.